Back to Search Start Over

TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY